StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Aggregate of 7 sell-side ratings as of 2026-05-01. Stonvex does not endorse these ratings.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Next report date, year-over-year trend, and recent quarter history.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $0.59 | $0.57 | -3.20% | 0.1M |
| 05-19 | $0.59 | $0.57 | -2.08% | 0.0M |
| 05-20 | $0.57 | $0.58 | +2.54% | 0.0M |
| 05-21 | $0.58 | $0.59 | +1.72% | 0.0M |
| 05-22 | $0.59 | $0.59 | +0.15% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Each factor shows OGEN's percentile within the scored universe — observational ranking, not a recommendation.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2023 2023-12-31 | Q3 2023 2023-09-30 | Q2 2023 2023-06-30 | Q1 2023 2023-03-31 |
|---|---|---|---|---|
Revenue | $37.65K | $37.65K | $30.19K | $17.02K |
Operating Income | $-20.90M | $-8.11M | $-6.01M | $-2.90M |
Net Income | $-20.66M | $-7.91M | $-3.05M | $-2.84M |
EPS (Diluted) | $-9.18 | $-3.70 | $-3.04 | $-1.41 |
Total Assets | $4.97M | $7.90M | $8.46M | $12.13M |
Total Liabilities | $1.80M | Not available | Not available | Not available |
Cash & Equivalents | $3.48M | $5.77M | $6.47M | $9.16M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 3.08M | 2.57M | 2.02M | 2.02M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.